All In Biotech

Drug Trial Radar · NCT06400485

AMT-676 in Patients With Advanced Solid Tumors

First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jun 18, 2024

Primary completion

May 15, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Multitude Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.

Conditions

  • Advanced Solid Tumors

Interventions

  • AMT-676Drug

    Participants will receive AMT-676 administered intravenously. Participants will be observed for first instance of dose limiting toxicities (DLT).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D)Time frame: 30 days after the last dose of IMP
  2. Maximum Tolerated Dose (MTD)Time frame: 30 days after the last dose of IMP
  3. Type, incidence and severity of Adverse EventsTime frame: 30 days after the last dose of IMP

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Carolina Biooncology Institute

    Huntersville, North Carolina, American Samoa · Not yet recruiting

  • John Hopkins Sidney Kimmel Comprehensive Cancer Center

    Philadelphia, Pennsylvania, American Samoa · Not yet recruiting

  • South Texas Accelerated Research Therapeutics (start) San Antonio

    San Antonio, Texas, American Samoa · Not yet recruiting

  • SCIENTIA Clinical Research Ltd

    Randwick, New South Wales, Australia · Recruiting

  • Macquarie University Hospital

    Macquarie, New South wWales, Australia · Recruiting

  • Gallipoli Medical Research Foundation

    Greenslopes, Queensland, Australia · Recruiting

  • Cabrini Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Linear Research

    Nedlands, Western Australia, Australia · Recruiting

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Not yet recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Not yet recruiting

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.